Drug intelligence / Profile preview

D569

Development stage: Unknown
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D569 is a pharmaceutical drug developed by Chong Kun Dang Pharmaceutical. It is likely a generic version of tofacitinib, a Janus kinase (JAK) inhibitor. Tofacitinib works by inhibiting the activity of JAK enzymes, which play a crucial role in immune system signaling and inflammatory processes.

Other names: CKD-374 5mg tab.CKD374 5mg tab.CKD 374 5mg tab.

Targets

JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)JAK3 (Janus kinase 3)

Beyond the preview

Go deeper on D569.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D569.

Explore the full profile